RNA, U2 small nuclear 32, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-32P profile across patient tissues and cancer cell-line models. RNU2-32P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RNU2-32P is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RNU2-32P RNA expression shows 6,099 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, COAD, and STAD as cancer lineages where RNU2-32P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-32P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-32P survival associations across molecular data types. RNU2-32P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-32P RNA expression–survival associations across cancer types. High RNU2-32P expression shows unfavorable associations in SKCM, LIHC, MESO, OV, THCA and DLBC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RNU2-32P RNA expression.
This table summarizes RNU2-32P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-32P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-32P shows lower tumor expression in HNSC and THCA and higher tumor expression in COAD and LUSC. The COAD box plot shows higher RNU2-32P RNA expression in tumor versus normal tissue (log2 FC = +0.205, t-test p = .025).
This table shows molecular features associated with RNU2-32P in patient tissues and cancer cell lines. In patient samples, RNU2-32P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
